摘要
重症肌无力(Myasthenia gravis)是一种由自身抗体介导的自身免疫性疾病,在本病中,以机体产生的拮抗神经肌肉接头处的各类抗体为特征性生物标志物。对于加用糖皮质激素或二线免疫抑制剂的时机选择以及二线免疫抑制剂的种类选择方面仍然存在争议。本文就重症肌无力的目前治疗方式以及可能即将推出的新药进行综述如下。
Myasthenia gravis is an autoimmune disease mediated by autoantibodies. In this disease, various antibodies produced by the body that antagonize neuromuscular junctions are characteristic bi-omarkers. There is still controversy over the timing of adding glucocorticoids or second-line immunosuppressants, as well as the selection of types of second-line immunosuppressants. This article provides a review of the current treatment methods for myasthenia gravis and potential upcoming new drugs.
出处
《临床医学进展》
2024年第2期4252-4259,共8页
Advances in Clinical Medicine
